A corneal device comprising a base surface and a top surface, and having a water content ranging from about 78%-92% (w/w), inclusive. The corneal device can be used to treat, for example without limitation, ectatic corneal disease by supporting corneal structure weakened by the disease and/or changing an anterior curvature of the cornea.

A corneal device comprising a base surface and a top surface, and having a water content ranging from about 78%-92% (w/w), inclusive. The corneal device can be used to treat, for example without limitation, ectatic corneal disease by supporting corneal structure weakened by the disease and/or changing an anterior curvature of the cornea.

Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

The present invention provides a composition for restoration of tissue including a biodegradable polymeric copolymer which is obtained by polymerizing a hydrophobic biodegradable polymer and a hydrophilic biodegradable polymer. The composition of the present invention has excellent tissue restoration effects because of high collagen production rate without occurrence of nodules even when injected directly into the dermis, unlike the conventional composition for restoration of tissue.

The present invention provides a composition for restoration of tissue including a biodegradable polymeric copolymer which is obtained by polymerizing a hydrophobic biodegradable polymer and a hydrophilic biodegradable polymer. The composition of the present invention has excellent tissue restoration effects because of high collagen production rate without occurrence of nodules even when injected directly into the dermis, unlike the conventional composition for restoration of tissue.

The present invention provides a composition for restoration of tissue including a biodegradable polymeric copolymer which is obtained by polymerizing a hydrophobic biodegradable polymer and a hydrophilic biodegradable polymer. The composition of the present invention has excellent tissue restoration effects because of high collagen production rate without occurrence of nodules even when injected directly into the dermis, unlike the conventional composition for restoration of tissue.

The present invention provides a UV-curable pressure-sensitive adhesive composition, comprising: 81 to 97.5 parts of (meth)acrylate polymer having a carboxyl functional group by weight, the amount of the carboxyl functional group in the (meth)acrylate polymer having the carboxyl functional group being equal to or greater than 40 mmol/100 g; 2.5 to 19 parts of an epoxy resin by weight; 0.3 to 6 parts of a polyol by weight; and 0.05 to 5 parts of a photoinitiator by weight. The UV-curable pressure-sensitive adhesive composition has good anti-repulsion. The present invention further provides a UV-curable adhesive tape comprising the UV-curable pressure-sensitive adhesive composition.

The present invention provides a UV-curable pressure-sensitive adhesive composition, comprising: 81 to 97.5 parts of (meth)acrylate polymer having a carboxyl functional group by weight, the amount of the carboxyl functional group in the (meth)acrylate polymer having the carboxyl functional group being equal to or greater than 40 mmol/100 g; 2.5 to 19 parts of an epoxy resin by weight; 0.3 to 6 parts of a polyol by weight; and 0.05 to 5 parts of a photoinitiator by weight. The UV-curable pressure-sensitive adhesive composition has good anti-repulsion. The present invention further provides a UV-curable adhesive tape comprising the UV-curable pressure-sensitive adhesive composition.

A curable perfluoropolyether adhesive composition containing the following components (A) to (C): (A) 100 parts by mass of a linear perfluoropolyether compound having at least two alkenyl groups per molecule and having a perfluoropolyether structure containing a repeating unit represented by —C.sub.aF.sub.2aO— in a main chain, “a” being an integer of 1 to 6; (B) an effective curing amount of an organosilicon compound having at least two silicon-bonded hydrogen atoms per molecule; and (C) a catalytic amount of a hydrosilylation-reaction catalyst, where a cured product of the curable perfluoropolyether adhesive composition is an adhesive having adhesion of less than 0.5 N/25 mm.